{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:28Z","timestamp":1786982668805,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s13555-022-00797-9","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T06:04:30Z","timestamp":1664345070000},"page":"2613-2626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study"],"prefix":"10.1007","volume":"12","author":[{"given":"Cristina","family":"Pellegrini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Piaserico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Offidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Balestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mugheddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Malara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Schinzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"issue":"9997","key":"797_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Schon MP. Psoriasis Lancet. 2015;386(9997):983\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(14)61909-7.","journal-title":"Psoriasis Lancet"},{"issue":"3","key":"797_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","volume":"152","author":"ZC Chiesa Fuxench","year":"2016","unstructured":"Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the Health Improvement Network. JAMA Dermatol. 2016;152(3):282\u201390. https:\/\/doi.org\/10.1001\/jamadermatol.2015.4847.","journal-title":"JAMA Dermatol"},{"issue":"Suppl","key":"797_CR3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/jdv.12165","volume":"27","author":"C Pouplard","year":"2013","unstructured":"Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27(Suppl):336\u201346. https:\/\/doi.org\/10.1111\/jdv.12165.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"797_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","volume":"156","author":"S Vaengebjerg","year":"2020","unstructured":"Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(4):421\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0024.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"797_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.drudis.2020.10.023","volume":"26","author":"A Baylet","year":"2021","unstructured":"Baylet A, Laclaverie M, Marchand L, Bordes S, Closs-Gonthier B, Delpy L. Immunotherapies in cutaneous pathologies: an overview. Drug Discov Today. 2021;26(1):248\u201355. https:\/\/doi.org\/10.1016\/j.drudis.2020.10.023.","journal-title":"Drug Discov Today"},{"issue":"3","key":"797_CR6","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750\u201363. https:\/\/doi.org\/10.1016\/j.jaci.2019.04.029.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"797_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1314258.","journal-title":"N Engl J Med"},{"issue":"1","key":"797_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111. https:\/\/doi.org\/10.1186\/s13075-019-1882-2.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"797_CR9","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","volume":"56","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford). 2017;56(11):1993\u20132003. https:\/\/doi.org\/10.1093\/rheumatology\/kex301.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"797_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/jdv.16124","volume":"34","author":"K Reich","year":"2020","unstructured":"Reich K, Warren RB, Coates LC, Di Comite G. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34(6):1161\u201373. https:\/\/doi.org\/10.1111\/jdv.16124.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"797_CR11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2015.05.013.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"797_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jdv.16926","volume":"35","author":"A Nast","year":"2021","unstructured":"Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Cs\u00f6rg\u00f6 Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281\u2013317. https:\/\/doi.org\/10.1111\/jdv.16926.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"797_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1886231","author":"M Valenti","year":"2021","unstructured":"Valenti M, Pavia G, Gargiulo L, Facheris P, Sanna F, Borroni RG, et al. Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population. J Dermatolog Treat. 2021. https:\/\/doi.org\/10.1080\/09546634.2021.1886231.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"797_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14889","volume":"34","author":"F Bellinato","year":"2021","unstructured":"Bellinato F, Gisondi P, Maurelli M, Girolomoni G. IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review. Dermatol Ther. 2021;34(2): e14889. https:\/\/doi.org\/10.1111\/dth.14889.","journal-title":"Dermatol Ther"},{"issue":"12","key":"797_CR15","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1111\/jdv.15775","volume":"33","author":"G Odorici","year":"2019","unstructured":"Odorici G, Lasagni C, Bigi L, Pellacani G, Conti A. A real-life experience of psoriatic patients with history of cancer treated with biological drugs. J Eur Acad Dermatol Venereol. 2019;33(12):e453\u20135. https:\/\/doi.org\/10.1111\/jdv.15775.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"797_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1970706","author":"L Mastorino","year":"2021","unstructured":"Mastorino L, Dapavo P, Avallone G, Merli M, Cariti C, Rubatto M, et al. Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? J Dermatolog Treat. 2021. https:\/\/doi.org\/10.1080\/09546634.2021.1970706.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"797_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","volume":"75","author":"PC van de Kerkhof","year":"2016","unstructured":"van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83\u201398. https:\/\/doi.org\/10.1016\/j.jaad.2016.03.024.","journal-title":"J Am Acad Dermatol"},{"key":"797_CR18","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program. Overview of the SEER program. 2022. http:\/\/seer.cancer.gov\/about\/overview.html."},{"issue":"4","key":"797_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844\u201354. https:\/\/doi.org\/10.1111\/bjd.12214.","journal-title":"Br J Dermatol"},{"issue":"4","key":"797_CR20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis. 2013;72(4):517\u201324. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201244.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"797_CR21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/bjd.20136","volume":"185","author":"M Lebwohl","year":"2021","unstructured":"Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W, et al. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol. 2021;185(5):935\u201344. https:\/\/doi.org\/10.1111\/bjd.20136.","journal-title":"Br J Dermatol"},{"issue":"1","key":"797_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/15476910801897953","volume":"5","author":"C Dong","year":"2008","unstructured":"Dong C. IL-23\/IL-17 biology and therapeutic considerations. J Immunotoxicol. 2008;5(1):43\u20136. https:\/\/doi.org\/10.1080\/15476910801897953.","journal-title":"J Immunotoxicol"},{"issue":"8","key":"797_CR23","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/jid.2015.144","volume":"135","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Lebwohl MG, Bissonnette R. IL-23\/IL-17A dysfunction phenotypes inform possible clinical effects from anti-IL-17A therapies. J Invest Dermatol. 2015;135(8):1946\u201353. https:\/\/doi.org\/10.1038\/jid.2015.144.","journal-title":"J Invest Dermatol"},{"key":"797_CR24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190297","author":"J Zhao","year":"2020","unstructured":"Zhao J, Chen X, Herjan T, Li X. The role of interleukin-17 in tumor development and progression. J Exp Med. 2020. https:\/\/doi.org\/10.1084\/jem.20190297.","journal-title":"J Exp Med"},{"issue":"6","key":"797_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14044","volume":"33","author":"A Carpentieri","year":"2020","unstructured":"Carpentieri A, Mascia P, Fornaro M, Beylot-Barry M, Taieb A, Foti C, et al. Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: a multicenter real-life study. Dermatol Ther. 2020;33(6): e14044. https:\/\/doi.org\/10.1111\/dth.14044.","journal-title":"Dermatol Ther"},{"issue":"8","key":"797_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/14712598.2019.1622678","volume":"19","author":"M Megna","year":"2019","unstructured":"Megna M, Di Costanzo L, Argenziano G, Balato A, Colasanti P, Cusano F, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther. 2019;19(8):855\u201361. https:\/\/doi.org\/10.1080\/14712598.2019.1622678.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"797_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jaad.2019.02.062","volume":"81","author":"JM Ortiz-Salvador","year":"2019","unstructured":"Ortiz-Salvador JM, Saneleuterio-Temporal M, Magdaleno-Tapial J, Velasco-Pastor M, Pujol-Marco C, Sahuquillo-Torralba A, et al. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. J Am Acad Dermatol. 2019;81(2):427\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.062.","journal-title":"J Am Acad Dermatol"},{"key":"797_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001519","author":"R Ramonda","year":"2021","unstructured":"Ramonda R, Lorenzin M, Carriero A, Chimenti MS, Scarpa R, Marchesoni A, et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open. 2021. https:\/\/doi.org\/10.1136\/rmdopen-2020-001519.","journal-title":"RMD Open"},{"issue":"5","key":"797_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/ijd.14819","volume":"59","author":"R Ruiz-Villaverde","year":"2020","unstructured":"Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Galan-Gutierrez M, Armario HJC, Martinez-Pilar L. Drug survival, discontinuation rates, and safety profile of secukinumab in real-world patients: a 152-week, multicenter, retrospective study. Int J Dermatol. 2020;59(5):633\u20139. https:\/\/doi.org\/10.1111\/ijd.14819.","journal-title":"Int J Dermatol"},{"issue":"2","key":"797_CR30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/jdv.15962","volume":"34","author":"D Tha\u00e7i","year":"2020","unstructured":"Tha\u00e7i D, K\u00f6rber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, et al. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. J Eur Acad Dermatol Venereol. 2020;34(2):310\u20138. https:\/\/doi.org\/10.1111\/jdv.15962.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"797_CR31","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/jdv.16180","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Jullien D, Martin A, Peralta C. Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34(6):1174\u201385. https:\/\/doi.org\/10.1111\/jdv.16180.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00797-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T05:39:54Z","timestamp":1666417194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00797-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00797-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}